Uroguanylin inhibits proliferation of pancreatic cancer cells

References

• Ries L, Eisner M, Kosary C, Hankey, B., Miller, B., Clegg, L., , et al 2004. SEER cancer statistics review. Bethesda, MD: National Cancer Institute; 1975–2001.
   Google Scholar
• Hochster HS, Haller DG, de Gramont A, Berlin JD, Philip PA, Moore MJ, , et al. Consensus report of the International Society of Gastrointestinal Oncology on therapeutic progress in advanced pancreatic cancer. Cancer 2006; 107:676–85.
   Google Scholar
• Forte LR. Uroguanylin and guanylin peptides: pharmacology and experimental therapeutics. Pharmacol Therap 2004; 104: 137–62
   PubMed Web of Science ®Google Scholar
• Currie MG, Fok KF, Kato J, Moore RJ, Hamra FK, Duffin KL, et al. Guanylin: an endogenous activator of intestinal guanylate cyclase. Proc Natl Acad Sci USA 1992; 89: 947–51
   PubMed Web of Science ®Google Scholar
• Hamra FK, Forte LR, Eber SL, Pidhorodeckyj NV, Krause WJ, Freeman RH, et al. Uroguanylin: structure and activity of a second endogenous peptide that stimulates intestinal guanylate cyclase. Proc Natl Acad Sci USA 1993; 90: 10464–8
   PubMed Web of Science ®Google Scholar
• Kulaksiz H, Schmid A, Hönscheid M, Ramaswamy A, Cetin Y. Clara cell impact in air-side activation of CFTR in small pulmonary airways. Proc Natl Acad Sci USA 2002; 99: 6796–801
   PubMed Web of Science ®Google Scholar
• Kulaksiz H, Schlenker T, Rost D, Stiel A, Volkmann M, Lehnert T, et al. Guanylin regulates chloride secretion in the human gallbladder via the bile fluid. Gastroenterology 2004; 126: 732–40
   PubMed Web of Science ®Google Scholar
• Kulaksiz H, Schmid A, Hönscheid M, Eissele R, Klempnauer J, Cetin Y. Guanylin in the human pancreas: a novel luminocrine regulatory pathway of electrolyte secretion via cGMP and CFTR in the ductal system. Histochem Cell Biol 2001; 115: 131–45
   PubMed Web of Science ®Google Scholar
• Kulaksiz H, Rehberg E, Stremmel W, Cetin Y. Guanylin and functional coupling proteins in the human salivary glands and gland tumors. Am J Pathol 2002; 161: 655–64
   PubMed Web of Science ®Google Scholar
• Schulz S, Green CK, Yuen PS, Garbers DL. Guanylyl cyclase is a heat-stable enterotoxin receptor. Cell 1990; 63: 941–8
   PubMed Web of Science ®Google Scholar
• Cuthbert AW, Hickman ME, MacVinish LJ, Evans MJ, Colledge WH. Chloride secretion in response to guanylin in colonic epithelia from normal and transgenic cystic fibrosis mice. Br J Pharmacol 1994; 112: 31–6
   PubMedGoogle Scholar
• Shailubhai K, Yu HH, Karunanandaa K, Wang JY, Eber SL, Wang Y, et al. Uroguanylin treatment suppresses polyp formation in the Apc(Min/ + ) mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP. Cancer Res 2000; 60: 5151–7
   PubMed Web of Science ®Google Scholar
• Cohen MB, Hawkins JA, Witte DP. Guanylin mRNA expression in human intestine and colorectal adenocarcinoma. Lab Invest 1998; 78: 101–8
   PubMed Web of Science ®Google Scholar
• Pitari GM, Di Guglielmo MD, Park J, Schulz S, Waldman SA. Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells. Proc Natl Aca Sci USA 2001; 98: 7846–51
   PubMed Web of Science ®Google Scholar
• Mann EA, Steinbrecher KA, Stroup C, Witte DP, Cohen MB, Giannella RA. Lack of guanylyl cyclase C, the receptor for Escherichia coli heat-stable enterotoxin, results in reduced polyp formation and increased apoptosis in the multiple intestinal neoplasia (Min) mouse model. Int J Cancer 2005; 116: 500–5
   PubMedGoogle Scholar
• Kulaksiz H, Cetin Y. Uroguanylin and guanylate cyclase C in the human pancreas: expression and mutuality of ligand/receptor localization as indicators of intercellular paracrine signaling pathways. J Endocrinol 2001; 170: 267–75
   PubMed Web of Science ®Google Scholar
• Stanger BZ, Dor Y. Dissecting the cellular origins of pancreatic cancer. Cell Cycle 2006; 5: 43–6
   PubMed Web of Science ®Google Scholar
• Bockman DE, Guo J, Buchler P, Muller MW, Bergmann F, Friess H. Origin and development of the precursor lesions in experimental pancreatic cancer in rats. Lab Invest 2003; 83: 853–9
   PubMedGoogle Scholar
• de Sauvage FJ, Keshav S, Kuang WJ, Gillett N, Henzel W, Goeddel DV. Precursor structure, expression, and tissue distribution of human guanylin. Proc Natl Acad Sci USA 1992; 89: 9089–93
   PubMed Web of Science ®Google Scholar
• Miyazato M, Nakazato M, Yamaguchi H, Date Y, Kojima M, Kangawa K, et al. Cloning and characterization of a cDNA encoding a precursor for human uroguanylin. Biochem Biophys Res Commun 1996; 219: 644–8
   PubMedGoogle Scholar
• Cetin Y, Kuhn M, Kulaksiz H, Adermann K, Bargsten G, Grube D, et al. Enterochromaffin cells of the digestive system: cellular source of guanylin, a guanylate cyclase-activating peptide. Proc Natl Acad Sci USA 1994; 91: 2935–9
   PubMedGoogle Scholar
• de Sauvage FJ, Camerato TR, Goeddel DV. Primary structure and functional expression of the human receptor for Escherichia coli heat-stable enterotoxin. J Biol Chem 1991; 266: 17912–8
   PubMedGoogle Scholar
• Pitari GM, Zingman LV, Hodgson DM, Alekseev AE, Kazerounian S, Bienengraeber M, et al. Bacterial enterotoxins are associated with resistance to colon cancer. Proc Natl Acad Sci USA 2003; 100: 3018–20
   PubMedGoogle Scholar
• Zhu ZW, Friess H, Wang L, Bogardus T, Korc M, Kleeff J, et al. Nerve growth factor exerts differential effects on the growth of human pancreatic cancer cells. Clin Cancer Res 2001; 7: 105–29
   PubMedGoogle Scholar
• Itakura J, Ishiwata T, Friess H, Fujii H, Matsumoto Y, Buchler MW, et al. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res 1997; 3: 1309–16
   PubMed Web of Science ®Google Scholar
• Shi X, Liu S, Kleeff J, Friess H, Büchler MW. Acquired resistance of pancreatic cancer cells towards 5-fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 2002; 62: 354–62
   PubMed Web of Science ®Google Scholar
• Carpick BW, Gariepy J. The Escherichia coli heat-stable enterotoxin is a long-lived superagonist of guanylin. Infect Immun 1993; 61: 4710–5
   PubMed Web of Science ®Google Scholar
• Hamra FK, Fan X, Krause WJ, Freeman RH, Chin DT, Smith CE, et al. Prouroguanylin and proguanylin: purification from colon, structure, and modulation of bioactivity by proteases. Endocrinology 1996; 137: 257–65
   PubMedGoogle Scholar